ACT001 is named as an intervention in 3 current clinical trials in our USA, Germany, Canada, Australia and Singapore registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Accendatech USA Inc (1). The most-studied condition is Recurrent Glioblastoma Multiforme(GBM).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
NCT06838676 · ClinicalTrials.gov ↗ · Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG
|
Phase 2 | Recruiting | Nationwide Children's Hospital | Germany, Canada, Australia |
|
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
NCT06894225 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma
|
Phase 2 | Recruiting | National Neuroscience Institute | Singapore |
|
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
NCT05053880 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma Multiforme(GBM)
|
Phase 1/2 | Active, closed | Accendatech USA Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Accendatech USA Inc | 1 |
| Nationwide Children's Hospital | 1 |
| National Neuroscience Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Australia | 1 | 1 |
| Clinical trials in Singapore | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Germany, Canada, Australia and Singapore registers name ACT001 as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Germany, 1 with sites in Canada, 1 with sites in Australia and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Accendatech USA Inc (1), Nationwide Children's Hospital (1) and National Neuroscience Institute (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ACT001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ACT001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ACT001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.